Director Suzanne Louise Topalian filed a Form 4 with the SEC on October 28, 2026, reporting the acquisition of restricted stock units and stock options in Vir Biotechnology, Inc. (NASDAQ:VIR) on October 27, 2026.

Key Highlights

  • RSU grant (annual vesting): Topalian acquired 8,000 RSUs at $0 cost, with one-third vesting on October 27, 2027 and the remainder in two equal annual installments thereafter.
  • RSU grant (cliff vesting): Topalian acquired an additional 4,731 RSUs at $0 cost, vesting in full on the earlier of October 27, 2027 or the date of the issuer's next annual stockholder meeting.
  • Stock option grant (annual vesting): Topalian received a stock option to purchase 16,000 shares of common stock at an exercise price of $11.57, expiring October 26, 2036.
  • Stock option grant (cliff vesting): Topalian received a second stock option to purchase 9,462 shares of common stock at the same $11.57 exercise price, also expiring October 26, 2036.
  • Resulting ownership: Following these transactions, Topalian directly holds 12,731 shares of common stock and 25,462 shares underlying stock options.
  • Plan basis: All grants were made pursuant to the issuer's Equity Incentive Plan, according to the filing.

Vir Biotechnology Director Topalian Granted RSUs and Stock Options on October 27, 2026

According to the Form 4 filed on October 28, 2026, Suzanne Louise Topalian, a director of Vir Biotechnology, Inc. (NASDAQ:VIR), received two separate RSU grants and two stock option grants on October 27, 2026, all acquired at a price of $0 under the company's Equity Incentive Plan. The filing indicates these were acquisitions (transaction code "A") and not open-market purchases.

The first RSU grant of 8,000 units carries a three-year annual vesting schedule: one-third vests on October 27, 2027, with the remaining shares vesting in two equal annual installments thereafter. The second RSU grant of 4,731 units vests entirely on the earlier of October 27, 2027 or the date of the issuer's next annual meeting of stockholders, as stated in the filing's footnotes. Together, these two RSU grants bring Topalian's direct common stock holdings to 12,731 shares following the reported transactions.

On the derivative securities side, the filing reports two stock option grants to purchase common stock, each carrying an exercise price of $11.57 per share and an expiration date of October 26, 2036. The option for 16,000 shares vests one-third on October 27, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter. The option for 9,462 shares vests in full on the earlier of October 27, 2027 or the next annual stockholder meeting date. Following these grants, Topalian directly holds options covering a total of 25,462 shares, according to the filing. The Form 4 was signed by Vanina de Verneuil as Attorney-In-Fact on October 28, 2026.

What Was Disclosed

Director Suzanne Louise Topalian reported the acquisition of 12,731 RSUs and stock options covering 25,462 shares of Vir Biotechnology common stock on October 27, 2026, all granted at $0 cost under the company's Equity Incentive Plan, with varying vesting schedules tied to time or the next annual meeting.